The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pulmonary fibrosis
Publications
Chlorambucil-induced acute interstitial pneumonitis.
Case reports in hematology. 2014;2014:575417
Interstitial lung disease--an underdiagnosed side effect of chlorambucil?
Annals of hematology. 1993;67(6):305-7
Fatal interstitial pneumonitis following high-dose intermittent chlorambucil therapy for chronic lymphocyte leukemia.
Cancer. 1981;47(1):32-6
[Alveolitis and lung fibrosis following therapy with chlorambucil].
Praxis und Klinik der Pneumologie. 1984;38(3):108-11
Possible pulmonary effects of alkylating agents.
The New England journal of medicine. 1972;287(22):1150-1
Chlorambucil induced pulmonary fibrosis: report of a case and review.
Virginia medical. 1986;113(11):677-80
Chlorambucil lung toxicity.
Acta haematologica. 1990;83(3):156-8
Pulmonary disease with chlorambucil therapy.
Cancer. 1978;41(2):455-9
Interstitial pneumonia and chlorambucil.
Chest. 1979;76(4):471-3
Fatal intraalveolar and interstitial lung fibrosis in chlorambucil-treated chronic lymphocytic leukemia.
The Mount Sinai journal of medicine, New York. 1977;44(6):847-51